Experimental and clinical studies with somatostatin analogue octreotide in small cell lung cancer
1991

Effects of Octreotide in Small Cell Lung Cancer

Sample size: 20 publication Evidence: low

Author Information

Author(s): V.M. Macaulay, I.E. Smith, M.J. Everard, J.D. Teale, J.-C. Reubi, J.L. Millar

Primary Institution: Royal Marsden Hospital and Institute of Cancer Research

Hypothesis

Does octreotide have an anti-tumor effect in small cell lung cancer patients?

Conclusion

Octreotide treatment showed no significant anti-tumor activity in small cell lung cancer patients.

Supporting Evidence

  • Octreotide was well tolerated by most patients.
  • Serum insulin-like growth factor-I levels were suppressed during treatment.
  • None of the patients showed significant tumor response to octreotide.

Takeaway

Doctors tested a medicine called octreotide to see if it could help people with a type of lung cancer, but it didn't work as they hoped.

Methodology

The study involved treating 20 patients with octreotide and measuring tumor markers and growth inhibition in cell lines.

Limitations

The study had a small sample size and did not show significant clinical benefits.

Participant Demographics

20 patients with small cell lung cancer, including 6 previously untreated and 14 relapsed after chemotherapy.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication